Vanguard Group Inc. Grows Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Vanguard Group Inc. boosted its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 1.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 15,596,480 shares of the biopharmaceutical company's stock after purchasing an additional 209,190 shares during the period. Vanguard Group Inc. owned about 10.02% of TG Therapeutics worth $469,454,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TGTX. Blue Trust Inc. lifted its holdings in TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 371 shares in the last quarter. Smartleaf Asset Management LLC raised its position in shares of TG Therapeutics by 512.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock valued at $60,000 after purchasing an additional 1,594 shares during the period. Jones Financial Companies Lllp lifted its stake in shares of TG Therapeutics by 460.7% during the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock valued at $64,000 after buying an additional 1,737 shares in the last quarter. Synergy Asset Management LLC bought a new position in TG Therapeutics in the 4th quarter worth $75,000. Finally, GAMMA Investing LLC raised its holdings in TG Therapeutics by 562.4% during the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company's stock valued at $77,000 after acquiring an additional 2,171 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on TGTX shares. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $40.67.

TG Therapeutics Price Performance

Shares of NASDAQ:TGTX traded down $1.99 during mid-day trading on Friday, reaching $37.35. The stock had a trading volume of 3,137,631 shares, compared to its average volume of 3,083,830. The business's 50 day moving average price is $35.27 and its 200 day moving average price is $30.89. TG Therapeutics, Inc. has a 1 year low of $12.93 and a 1 year high of $43.32. The company has a market cap of $5.87 billion, a P/E ratio of -373.46 and a beta of 2.13. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.07. The business had revenue of $108.19 million for the quarter, compared to analysts' expectations of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. Research analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Insider Activity at TG Therapeutics

In other news, CFO Sean A. Power sold 10,021 shares of the business's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the sale, the chief financial officer now directly owns 660,611 shares in the company, valued at $18,847,231.83. The trade was a 1.49 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 10.50% of the stock is owned by insiders.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.